TNF and rheumatoid arthritis: Biologic agents such as rituximab (RTX) or tumor necrosis factor-α (TNF-α) inhibitors are reserved for a small subset of refractory cases, particularly in patients with overlapping features of RA (Carsons et al., 2017).